Oxilorphan

From Self-sufficiency
Revision as of 14:29, 16 April 2010 by El3ctr0nika (Talk)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Oxilorphan
140px
Systematic (IUPAC) name
(-)-17-(cyclopropylmethyl)-morphinan-3,14-diol
Identifiers
CAS Number 42281-59-4
ATC code none
PubChem CID 5361090
Chemical data
Formula C20H27NO2
Molar mass 313.44 g/mol[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Oxilorphan is an opioid antagonist from the morphinan family of drugs.

Oxilorphan is a non-selective opioid which is a μ antagonist but a κ partial agonist. It has similar effects to naloxone, and around the same potency as an antagonist.[1]

Oxilorphan has some weak partial agonist effects[2] and can produce hallucinogenic effects at high doses, suggesting some kappa opioid agonist action.[3] It was trialled for the treatment of opiate addiction, but was not developed commercially.[4]

See also

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


  1. ↑ Pircio AW, Gylys JA. Oxilorphan (l-N-cyclopropylmethyl-3,14-dihydroxymorphinan): a new synthetic narcotic antagonist. Journal of Pharmacology and Experimental Therapeutics. 1975 Apr;193(1):23-34.
  2. ↑ Sellers EM, Thakur R. Partial agonist properties and toxicity of oral oxilorphan. Journal of Clinical Pharmacology. 1976 Apr;16(4):183-7.
  3. ↑ Leander JD. Evidence that nalorphine, butorphanol and oxilorphan are partial agonists at a kappa-opioid receptor. European Journal of Pharmacology. 1983 Jan 21;86(3-4):467-70.
  4. ↑ Tennant FS Jr, Tate JA, Ruckel E. Clinical trial in post-addicts with oxilorphan (levo-BC-2605): a new narcotic antagonist. Drug and Alcohol Dependence. 1976 Jun;1(5):329-37.
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Oxilorphan&oldid=23305"